Kimura Masakazu, Miyajima Kuniharu, Kojika Masakazu, Kono Takafumi, Kato Harubumi
Department of Thoracic Surgery, Niizashiki Central General Hospital, 1-7-2 Touhoku, Niiza, Saitama 352-0001, Japan.
Int J Mol Sci. 2015 Oct 23;16(10):25466-75. doi: 10.3390/ijms161025466.
Intractable advanced lung cancer can be treated palliatively with photodynamic therapy (PDT) combined with chemotherapy to remove central and peripheral (lobar or segmental bronchi) bronchial stenosis and obstruction. We present data for 12 (eight men, four women) consecutive patients with 13 advanced non-small cell lung carcinomas in whom curative operations were contraindicated, who underwent PDT combined with chemotherapy for local control of the intraluminal lesions. The mean age was 73.3 years (range, 58-80 years), and the stages of cancer were IIA-IV. The median stenosis rates before treatment, one week post-treatment, and one month post-treatment were 60% (range, 30%-100%), 15% (range, 15%-99%), and 15% (range 15%-60%), respectively. The mean and median survival times were 9.3 and 5.9 months, respectively. The overall 1-year survival rate was 30.0%. No PDT-related morbidity or mortality occurred. In this single-institution study, all patients experienced improved symptoms and quality of life at one week after treatment; furthermore, an objective response was evidenced by the substantial increase in the openings of the bronchial lumen and prevention of obstructive pneumonia. Therefore, PDT with chemotherapy was useful and safe for the treatment of bronchial obstruction.
难治性晚期肺癌可采用光动力疗法(PDT)联合化疗进行姑息治疗,以消除中央和外周(叶或段支气管)支气管狭窄和阻塞。我们提供了连续12例(8名男性,4名女性)患有13例晚期非小细胞肺癌患者的数据,这些患者因禁忌进行根治性手术,接受了PDT联合化疗以局部控制腔内病变。平均年龄为73.3岁(范围58 - 80岁),癌症分期为IIA - IV期。治疗前、治疗后1周和治疗后1个月的中位狭窄率分别为60%(范围30% - 100%)、15%(范围15% - 99%)和15%(范围15% - 60%)。平均生存时间和中位生存时间分别为9.3个月和5.9个月。总体1年生存率为30.0%。未发生与PDT相关的发病率或死亡率。在这项单机构研究中,所有患者在治疗后1周症状和生活质量均有所改善;此外,支气管腔开口显著增加以及预防阻塞性肺炎证明了客观缓解。因此,PDT联合化疗对支气管阻塞的治疗是有效且安全的。